skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Maximize pharmaceutical market access potential

RxScorecard | Pharma intelligence

Payers now hold the power behind reimbursable prescribing decisions.

Insight into how payers evaluate drugs, one against another, is crucial to any successful drug launch.

 

How it helps
RxScorecard delivers objective data – from a payers’ perspective – via a web-based tool. Use it to:

  • Define your development path and specific data requirements that differentiate pipeline candidates to payers
  • Reveal where the value of your drug lies alongside its competitors
  • See how the comparative value of a drug is differentiated within a therapeutic area by class and patient sub-population
  • Align internal stakeholders around a common understanding of what payers value
  • Evaluate future potential and improve value proposition: interactively create custom scenarios using your own proprietary data to test the impact of different assumptions – all in real-time

 

How it works
RxScorecard™ objectively shows how your payer customers will see your product and those of your competitors. Access scores for competitive drugs on all key efficacy, safety, adherence, and economic metrics most meaningful for payers. Gain powerful insight into how you can effectively differentiate your drug and maximize its market potential.

無料の最新記事&レポート

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Medical Aesthetics: A Untapped Pharma Market With Incoming Competition

    05 Dec 2018

    Medical aesthetics is a unique biopharmaceutical niche that may scare off companies due to the consumer marketing and doctor relationship-building skills needed to compete in this market, but the potential for growth keeps major players engaged and searching for new technology.

    Topic BioPharmaceutical

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース, Pink Sheet: 世界の薬事規制と承認審査に関するニ...

    医療用医薬品、医療機器、薬事規制ニュース配信サービス

    09 Nov 2018

    Pharma Intelligence offers a wealth of pharmaceutical industry news and strategic insight into the healthcare & biotechnology markets from around the world. Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.

  • In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース

    Broader Capabilities Keep Consort On Top At Device End Of Drug Delivery

    06 Sep 2018

    Drug delivery technology specialist Consort Medical has capitalized on device respiratory expertise for 50 years, but a renewed focus on strategic expansion has seen it make an IP play, move into the pharma side and target other delivery formats for global pharma industry customers. Its enhanced capabilities will keep rivals on their toes.

    Topic drug-review drug-approval

  • In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース

    World In Motion The Shape Of The New Health Care Technology Ecosystem In 2022

    22 Aug 2018

    The health products industry, methods of care delivery and even the public's expectations for improved tools to prevent, monitor and treat disease have transformed dramatically in the past five years. The changes anticipated over a similar period ahead are potentially even more marked, with business continuity impacts for medtech and pharma concerns, according to Deloitte LLP experts who were on the circuit at health care industry events in Germany and the UK this spring.

    Topic Business strategies Digital Health

  • In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース

    Pharma’s New R&D Models: Federating Innovation

    By Melanie Senior 22 Aug 2018

    Experiments are underway to solve pharma’s well-documented R&D productivity crisis. The industry is no longer focused only on buying new drugs via M&A, or on outsourcing discovery. Companies are also building new channels through which to access innovation, setting up different kinds of partnerships, and using new kinds of data. The shift involves re-thinking pharma’s place in healthcare.

    Topic research drug-development-landscape

  • In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース

    Ortho Demand Pull: DePuy Synthes Shaping Its Digital And Robotic Surgery Strategy Around Patient Needs

    22 Aug 2018

    Johnson & Johnson's DePuy Synthes orthopedic business has taken a measured view of digital and robotic capabilities, rather than acquiring assets that perhaps do not fully meet its strategic needs. For the business's global R&D head Euan Thomson, any new technology must augment the group's abilities to drive meaningful outcomes.

    Topic digital-health

  • In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース

    Bayer’s US Playbook: The Smart Way To Top-Line Growth

    By William Looney 22 Aug 2018

    The hotly contested US market is central to Bayer’s aspirations to become a global innovation player in pharmaceuticals, especially in key growth segments like oncology. A little more than one year in, Bayer Pharmaceuticals Americas President Dr. Carsten Brunn reflects on his unit’s progress.

    Topic business-strategies company-analysis

  • In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース

    Back To The Future: Novo’s Sørensen Reflects On CEO Years And Tasks Ahead For Industry

    22 Aug 2018

    Lars Rebien Sørensen scrutinizes the pharmaceutical industry and shares with In Vivo his vision for the future of the Novo Nordisk Foundation. With 16 years as CEO of Novo Nordisk under his belt, as well as many more years in leadership roles at the Danish company, Sørensen reflects on the past and gives his predictions for the future of the innovative drug development sector.

    Topic Drug development landscape Business strategies

  • In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース

    Cancer's New Patient Demographic; Will Survivorship Change The Face Of Cancer Care?

    By William Looney 22 Aug 2018

    The 16 million survivors of cancer in the US today form a restless constituency with its own disparate set of interests – and by sheer weight of numbers is beginning to direct changes to medical practice that pose both risks and opportunity for biopharma.

    Topic cancer

  • In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース

    True Innovation In Women's Health Hindered Because Conditions Are Not Fatal

    17 Aug 2018

    Drug developers and financiers discuss the biggest challenges delaying novel R&D in diseases effecting only women and how poor awareness of the debilitating symptoms that come with some conditions has led to a lack of emphasis on innovative research.

    Topic drug-approval drug-review

  • In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース

    NASH: Flying The Plane While Building It

    By Amama Sadiq, Iliyana P. Atanasova, Katherine J. Franklin 03 Aug 2018

    Drug development for nonalcoholic steatohepatitis (NASH), a form of liver disease, is a game of incomplete information: pipeline evolution is occurring in parallel with continued efforts to better understand and manage the disease. To date, no therapy for patients with NASH has been approved and consequences of the condition can be severe, including cirrhosis and hepatocellular carcinoma.

    Topic Clinical trials

  • In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース

    Cancer Vaccines: Is There A Future Beyond Trial And Error?

    By William Looney 12 Jul 2018

    Strong foundational research in immunology and some promising early phase trial results have so far failed to expedite the validation of vaccines to treat cancer. In Vivo examines biopharma’s enduring optimism about the future of cancer vaccinology, including a closer look at one company’s platform to tackle the incurable malignancies that beset the mother of all organs: the human brain.

    Topic cancer vaccines

  • In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース

    Repositioning Market Access: A Function Fit For Purpose In A New Era Of Costly Cures

    By William Looney 15 May 2018

    On October 5, In Vivo convened a group of top market-access specialists and industry and investment analysts to consider a central strategic challenge facing all innovators in biopharma: how to pay for the next wave of cures. Finding the answer first depends on a rebranding of the function itself – it’s not market access to products; it’s patient access to progress.

    Topic strategy

  • In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース

    Pharma Sourcing And Procurement: The New Strategy Of Spend

    11 May 2018

    Just what does a strategic approach to sourcing and procurement mean for today’s biopharma enterprise?In Vivotalks to the practice leaders at two diversely representative companies – Adamas Pharmaceuticals and Roivant Sciences – to identify four essential characteristics of “best in class” purchasing performance: (1) Think big – be strategic. (2) Buy better – add value.  (3) Work fast – spend forward. (4) Reach out earn the business.

    Topic BioPharmaceutical

  • In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース

    Business As Usual Is Not A Vision For The Future - The Value-Based Shift Is Underway

    11 May 2018

    Value is a concept that is increasingly embraced by providers and payers, as well as medtech manufacturers. Leading providers are organizing around value, changing their models and thereby inviting medtech manufacturers to adapt to the post fee-for-service era. Some, like Medtronic, are at the head of the game.

医薬品産業専門のジャーナリスト&アナリスト

Management

Roger Longman

Management, Leadership Manager
Roger Longman

+27 year(s) experience

Management

Beth Nash

Management, MD Chief Medical Officer

Beth specializes in

  • Commercial Strategy

+22 year(s) experience

Management

Christine Blazynski, PhD

Management, Senior Product Manager, Special Projects
Christine Blazynski, PhD

Christine specializes in

  • Clinical Trials
  • Clinical trial strategy
  • Clinical trial benchmark analysis
  • Clinical trend analysis
  • Biopharma pipeline strategy

+21 year(s) experience

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

または下記のフォームよりご連絡下さい。

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。